New Data at AAN 2021 from Across Biogen’s MS Portfolio Demonstrate Positive Impact of Treatment on People Living with Relapsing Multiple Sclerosis - Seite 3

Biogen Continues Leading Research in MS
The presentations at AAN are part of Biogen’s ongoing commitment to the MS community, improving the understanding of the disease and advancing treatment through innovation. The company recently launched a subcutaneous injection of TYSABRI in Europe and an intramuscular administration of PLEGRIDY (peginterferon beta-1a) in the United States and Europe. Biogen currently has more than 25 MS clinical trials underway including research on considerations around COVID-19 vaccination for people with MS.

Data Presentations Featured at AAN:

• Impact of Natalizumab on Quality of Life in a Real-World Cohort of Patients with Multiple Sclerosis: Results from MS Partners Advancing Technology and Health Solutions (MS PATHS) – P15.023
• No Difference in Radiologic Outcomes for Natalizumab Patients on Extended Interval Dosing Compared with Standard Interval Dosing in MS PATHS – P15.210
• Natalizumab Extended Interval Dosing (EID) is Associated with a Reduced Risk of Progressive Multifocal Leukoencephalopathy (PML) Compared with Every-4-week (Q4W) Dosing: Updated Analysis of the TOUCH Prescribing Program Database – P15.201
• Multiple Sclerosis Patients Treated with Diroximel Fumarate in the Real-world Setting have High Rates of Persistence and Adherence – P15.227

About TYSABRI (natalizumab)
TYSABRI is a well-established relapsing multiple sclerosis (RMS) treatment indicated for relapsing forms of MS in adults that has been proven in clinical trials to slow physical disability progression, reduce the formation of new brain lesions and cut relapses. TYSABRI is approved in 80 countries, and over 220,000 people worldwide have been treated with TYSABRI, with over 880,000 patient-years of experience, based on clinical trials and prescription data.¹

TYSABRI increases the risk of progressive multifocal leukoencephalopathy (PML), a rare opportunistic viral infection of the brain which has been associated with death or severe disability. Risk factors that increase the risk of PML are the presence of anti-JC virus antibodies, prior immunosuppressant use and longer TYSABRI treatment duration. Patients who have all three risk factors have the highest risk of developing PML. When initiating and continuing treatment with TYSABRI, physicians should consider whether the expected benefit of TYSABRI is sufficient to offset this risk.